Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
"Dipeptidyl-Peptidases and Tripeptidyl-Peptidases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subclass of exopeptidases that includes enzymes which cleave either two or three AMINO ACIDS from the end of a peptide chain.
Below are MeSH descriptors whose meaning is more general than "Dipeptidyl-Peptidases and Tripeptidyl-Peptidases".
Below are MeSH descriptors whose meaning is more specific than "Dipeptidyl-Peptidases and Tripeptidyl-Peptidases".
This graph shows the total number of publications written about "Dipeptidyl-Peptidases and Tripeptidyl-Peptidases" by people in Harvard Catalyst Profiles by year, and whether "Dipeptidyl-Peptidases and Tripeptidyl-Peptidases" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 2 | 2 |
| 2004 | 1 | 0 | 1 |
| 2007 | 0 | 2 | 2 |
| 2008 | 0 | 1 | 1 |
| 2010 | 2 | 2 | 4 |
| 2012 | 3 | 1 | 4 |
| 2013 | 3 | 3 | 6 |
| 2014 | 2 | 3 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 1 | 1 | 2 |
| 2018 | 2 | 0 | 2 |
| 2019 | 5 | 4 | 9 |
| 2020 | 0 | 1 | 1 |
| 2021 | 2 | 1 | 3 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 3 | 3 |
Below are the most recent publications written about "Dipeptidyl-Peptidases and Tripeptidyl-Peptidases" by people in Profiles.
-
Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study. BMJ Open Diabetes Res Care. 2023 11; 11(6).
-
Omega-3 Fatty Acids Interact with DPP10 Region Genotype in Association with Childhood Atopy. Nutrients. 2023 May 22; 15(10).
-
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Metab. 2023 03; 49(2):101418.
-
Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2022 10 03; 5(10):e2235995.
-
DPP9 deficiency: An inflammasomopathy that can be rescued by lowering NLRP1/IL-1 signaling. Sci Immunol. 2022 09 16; 7(75):eabi4611.
-
A ubiquitin-independent proteasome pathway controls activation of the CARD8 inflammasome. J Biol Chem. 2022 07; 298(7):102032.
-
Effects of dipeptidyl peptidase-4 inhibitors and sulphonylureas on cognitive and physical function in nursing home residents. Diabetes Obes Metab. 2022 02; 24(2):247-256.
-
Dipeptidyl peptidase 9 sets a threshold for CARD8 inflammasome formation by sequestering its active C-terminal fragment. Immunity. 2021 07 13; 54(7):1392-1404.e10.
-
DPP9 sequesters the C terminus of NLRP1 to repress inflammasome activation. Nature. 2021 04; 592(7856):778-783.
-
Genetic mechanisms of critical illness in COVID-19. Nature. 2021 03; 591(7848):92-98.